The therapeutic armamentarium for inflammatory bowel disease (IBD) is expanding with the advent of anti–IL-23 therapies. The unique clinical profiles of new and emerging agents make it necessary that treatment decisions are guided by evolving knowledge of the science surrounding …
Lennox-Gastaut syndrome (LGS) remains a challenging condition to understand, diagnose, and manage. Neuroscience/neurology clinicians, including nurses and nurse practitioners (NPs), encounter significant challenges in the management of patients with LGS, due to the severe symptoms and morbidities, diagnostic delays, and …
Lennox-Gastaut syndrome (LGS) remains a challenging condition to understand, diagnose, and manage. Neuroscience/neurology clinicians, including nurses and nurse practitioners (NPs), encounter significant challenges in the management of patients with LGS, due to the severe symptoms and morbidities, diagnostic delays, and …
Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …
Significant therapeutic advancements have been made over the last decade for treatment of inflammatory bowel disease (IBD), a chronic condition that includes Crohn’s disease (CD) and ulcerative colitis (UC). The inflammatory cytokine interleukin (IL)-23 has been established as an active …
Biomarker and molecular testing to help oncologists match patients with the best cancer treatment can be challenging in the community oncology setting and in underserved communities. At present, patients with cancer in racially or ethnicly underserved communities are not receiving …
Crohn’s disease (CD) can cause progressive bowel damage, impaired quality of life, and permanent disability. Severity and presentation can vary widely from person to person, necessitating an individualized treatment approach. The use of more readily available imaging modalities such as …
Ulcerative colitis (UC) affects around three million people in the United States. Delays in treatment coverage approval, costs of managing the disease, and uncertainties around new treatment options significantly impact how well patients react to treatment, and short- and long-term …
Cytokines, such as interleukin (IL)-23, are key drivers of intestinal inflammation in patients with inflammatory bowel disease. While all IL-23–targeted agents neutralize IL-23, differences in antibody structure can improve the ability of these agents to capture this inflammatory cytokine from …